|
1
|
Ghoncheh M, Momenimovahed Z and Salehiniya
H: Epidemiology, incidence and mortality of breast cancer in Asia.
Asian Pac J Cancer Prev. 17:47–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
World. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Custodio-Santos T, Videira M and Brito MA:
Brain metastasization of breast cancer. Biochim Biophys Acta Rev
Cancer. 1868:132–147. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun B, Huang Z, Wu S, Ding L, Shen G, Cha
L, Wang J and Song S: Cystic brain metastasis is associated with
poor prognosis in patients with advanced breast cancer. Oncotarget.
7:74006–74014. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grolmusz VK, Karaszi K, Micsik T, Toth EA,
Meszaros K, Karvaly G, Barna G, Szabo PM, Baghy K, Matko J, et al:
Cell cycle dependent RRM2 may serve as proliferation marker and
pharmaceutical target in adrenocortical cancer. Am J Cancer Res.
6:2041–2053. 2016.PubMed/NCBI
|
|
6
|
Zhang H, Liu X, Warden CD, Huang Y, Loera
S, Xue L, Zhang S, Chu P, Zheng S and Yen Y: Prognostic and
therapeutic significance of ribonucleotide reductase small subunit
M2 in estrogen-negative breast cancers. BMC Cancer. 14:6642014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Meng L, Wang XW, Ma GY and Chen
JH: Expression of RRM1 and RRM2 as a novel prognostic marker in
advanced non-small cell lung cancer receiving chemotherapy. Tumour
Biol. 35:1899–1906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang CC, Lin CC, Wang CH, Huang CC, Ke
TW, Wei PL, Yeh KT, Hsu KC, Hsu NY and Cheng YW: miR-211 regulates
the expression of RRM2 in tumoral metastasis and recurrence
in colorectal cancer patients with a k-ras gene mutation.
Oncol Lett. 15:8107–8117. 2018.PubMed/NCBI
|
|
9
|
Putluri N, Maity S, Kommagani R, Creighton
CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T,
et al: Pathway-centric integrative analysis identifies RRM2 as a
prognostic marker in breast cancer associated with poor survival
and tamoxifen resistance. Neoplasia. 16:390–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang WH, Li N, Yuan ZQ, Qian XL and Wang
ZH: DSCAM-AS1 promotes tumor growth of breast cancer by reducing
miR-204-5p and up-regulating RRM2. Mol Carcinog. 58:461–473. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shah KN, Mehta KR, Peterson D, Evangelista
M, Livesey JC and Faridi JS: AKT-induced tamoxifen resistance is
overturned by RRM2 inhibition. Mol Cancer Res. 12:394–407. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu AG, Feng H, Wang PX, Han DP, Chen XH
and Zheng MH: Emerging roles of the ribonucleotide reductase M2 in
colorectal cancer and ultraviolet-induced DNA damage repair. World
J Gastroenterol. 18:4704–4713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dai L, Lin Z, Qiao J, Chen Y, Flemington
EK and Qin Z: Ribonucleotide reductase represents a novel
therapeutic target in primary effusion lymphoma. Oncogene.
36:5068–5074. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mannargudi MB and Deb S: Clinical
pharmacology and clinical trials of ribonucleotide reductase
inhibitors: Is it a viable cancer therapy? J Cancer Res Clin Oncol.
143:1499–1529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Mabhouh AA, Nation PN, Kaddoura A and
Mercer JR: Unexpected preferential brain metastases with a human
breast tumor cell line MDA-MB-231 in BALB/c nude mice. Vet Pathol.
45:941–944. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang Z, Gong C, Liu H, Zhang X, Mei L,
Song M, Qiu L, Luo S, Zhu Z, Zhang R, et al: E2F1 promote the
aggressiveness of human colorectal cancer by activating the
ribonucleotide reductase small subunit M2. Biochem Biophys Res
Commun. 464:407–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berghoff AS and Preusser M:
Anti-angiogenic therapies in brain metastases. Memo. 11:14–17.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Viallard C and Larrivee B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim LS, Huang S, Lu W, Lev DC and Price
JE: Vascular endothelial growth factor expression promotes the
growth of breast cancer brain metastases in nude mice. Clin Exp
Metastasis. 21:107–118. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buijs N, Oosterink JE, Jessup M,
Schierbeek H, Stolz DB, Houdijk AP, Geller DA and van Leeuwen PA: A
new key player in VEGF-dependent angiogenesis in human
hepatocellular carcinoma: Dimethylarginine dimethylaminohydrolase
1. Angiogenesis. 20:557–565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X,
Liu X, Zhou B and Yen Y: Overexpression of RRM2 decreases
thrombspondin-1 and increases VEGF production in human cancer cells
in vitro and in vivo: Implication of RRM2 in angiogenesis. Mol
Cancer. 8:112009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y, Zhang Y, Iwamoto H, Hosaka K, Seki
T, Andersson P, Lim S, Fischer C, Nakamura M, Abe M, et al:
Discontinuation of anti-VEGF cancer therapy promotes metastasis
through a liver revascularization mechanism. Nat Commun.
7:126802016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin Y, Feng SJ, Qiu S, Shao N and Zheng
JH: LncRNA MALAT1 promotes proliferation and metastasis in
epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med
Pharmacol Sci. 21:3176–3184. 2017.PubMed/NCBI
|
|
26
|
Chen H, Zhou L, Wu X, Li R, Wen J, Sha J
and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate
cancer. Front Biosci (Landmark Ed). 21:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu X, Sun L, Wang X, Su P, Li Z, Zhang C,
Wang Y, Gao P and Ma R: Breast cancer invasion and metastasis by
mPRalpha through the PI3K/Akt signaling pathway. Pathol Oncol Res.
22:471–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
